Shire Share Discussion Threads

[philanderer] 12/9/2017 12:48

Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants

By GlobeNewswire, September 12, 2017, 07:00:00 AM EDT

[philanderer] 11/9/2017 14:13

Having a right old go at breaking this downtrend :-)

[philanderer] 11/9/2017 13:09

Lexington, MA - September 11, 2017

- Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, announces positive topline Phase 3 results for the SAHARA(TM) study, a global, multi-center, randomized, double-blind, placebo-controlled, partial crossover trial that evaluated the efficacy and safety of subcutaneously administered C1 esterase inhibitor [human] Liquid for Injection, also referred to as SHP616 Liquid, versus placebo over two 14-week treatment periods in patients 12 years of age or older with symptomatic Hereditary Angioedema (HAE).

SHP616 is an investigational treatment administered subcutaneously, being evaluated for the prevention of angioedema attacks in patients with HAE-a rare genetic disease characterized by recurrent swelling of extremities, gastrointestinal tract, and upper airways.

[ruethewhirl] 11/9/2017 08:21

Stormin' on.

[mbmiah] 08/9/2017 22:12

A nice finish for a Friday. Let's see what next week brings.

[justiceforthemany] 08/9/2017 18:28

Yes Shire had a decent week but a long way off where it should be.

Portfolio -0.1% for the week so almost flat versus -0.8% for FTSE all share and that's despite Vectura losing 20% in 2 days + Go-Ahead plummeting 17% in 2 days also!
Retailers got hammered today also including MKS and KGF.
So all in all can't complain.

The butchery and savagery going on by short sellers and hedge funds these days is truly disgraceful. A slightly weak update and you've had it. Not in Greene King but read the LFL fell by 1.2% - hardly a reason for a 16% fall in SP?
Vectura is a respiratory drug specialist and reported recurring revenue was up 27%; Go-Ahead reported a rise in revenue and a 5% fall in profits - after the butchery it now yields 7% and has a P/E of 7.

Hikma suffered a similar dramatic fall recently and we know about Shire also.
No company is immune. Look at AZN also.

The amount of manipulation going on is incredible yet the FCA continue to turn a blind eye even when directly contacted and spoonfed information.

A slightly weak update should in a fair and logical world cause a drop in share price of 2-3% max not 20%!

It's a shorters dominated dirty and rogue market with insider trading rife as hell make no mistake. Bankers and traders have always been this way but they have reached extreme levels now.

[philanderer] 08/9/2017 17:20

Needed that for SHP , good end to the day and +100p for the week.


Portfolio kicked in the cobblers today by that GNK trading statement.

I'm -1.1% for the week but +8.6% for the year, well off the best though.

Good weekend everyone.

[mbmiah] 08/9/2017 15:02

Odd share price movement- fek is going on

[philanderer] 08/9/2017 10:09

That elusive 4000p :-)

morning everyone.

[montyhedge] 08/9/2017 09:03

Pe 121 dreamland.

[philanderer] 08/9/2017 00:30

Here's Why Shire PLC Stock Fell 10% in August


What happened

Shares of Shire PLC (NASDAQ: SHPG), a biopharmaceutical company that focuses on treatments for rare diseases, fell 9.94% in August, according to data from S&P Global Market Intelligence. Slipping sales figures for both a recently acquired hemophilia therapy and an aging attention deficit drug overshadowed an otherwise encouraging earnings report.


So what

Last June, Shire completed a $32 billion merger with Baxalta that appears to be firing on all cylinders except one: hemophilia. On a pro forma basis, combined product sales rose 7%, but inhibitor therapy sales to hemophiliacs fell 7% compared to the previous year period.

According to Shire, sales of its drug FEIBA (an acronym for factor eight inhibitor bypassing activity) should make up about 5% of the company's total revenue this year. FEIBA, which is prescribed to patients who have developed inhibitors that reduce the effectiveness of other clotting factor replacement therapies, earned its first approval 31 years ago.


Investors were also dismayed by Adderall XR's sales figures. Generic competition for the attention deficit disorder treatment pushed its Q2 sales down by 30% year over year.

Now what

At $71.4 million, Adderall XR sales comprised just 2% of Shire's total during the three-month period that ended June 30. While generics will likely squeeze sales of the drug even further, a recently launched follow-on treatment could partially offset those losses. Mydayis is essentially a 16-hour version of Adderall XR, which generally lasts for 12 hours.


Unfortunately, the company doesn't have a ready replacement for FEIBA. A gene therapy candidate for the treatment of hemophilia A, called SHP654, will enter clinical trials by the end of the year, but the company expects FEIBA sales to fall to 50% of present levels by 2022.

[philanderer] 07/9/2017 15:14

I keep a weekly check on mine too. So far pretty good, 122/78 monday afternoon.

4100p needed here to break this downtrend I reckon.

[essentialinvestor] 07/9/2017 14:34

Hi Phil, it is indeed. However due to high BP I'm now
drinking less than 10 units a week, there is hardly any point!.

In fairness I did enjoy about 30 units weekly for a number of years.

[philanderer] 07/9/2017 14:21

Well done EI :-D


You'll need it.... from memory , your neck of the woods ?


'At £4.40, Surrey becomes most expensive place in UK to buy a pint'

[essentialinvestor] 07/9/2017 13:46

I'm ahead, finally!.

[philanderer] 07/9/2017 13:17

And right on time...

Shire to participate at two upcoming investor conferences

Lexington, MA, USA - September 7, 2017

- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will present at the Bank of America Merrill Lynch Global Healthcare Conference 2017 on September 14, 2017 at 1:45 p.m. BST (8:45 a.m. EDT) and Jeff Poulton, Chief Financial Officer will participate at the Morgan Stanley Global Healthcare Conference on September 12, 2017 at 3:30 p.m. EDT (8:30 p.m. BST).

The live audio webcasts of both events will be available on Shire's Investor website at Subsequently, a replay of both events will be available on this same website

[philanderer] 07/9/2017 09:38

Need some news to get this moving now , momentum in the right direction.

[philanderer] 07/9/2017 09:12

4000p , blink and you missed it ;-)


Morning guys.

[philanderer] 06/9/2017 23:35

mbmiah, the dividend is only a couple of pennies.

[mbmiah] 06/9/2017 22:44

I thought share price drops on ex div - surprise me, please

[justiceforthemany] 06/9/2017 21:19

Closed up 2% in the US; DOW up 0.25%

4037p is the first resistance point

[philanderer] 06/9/2017 20:44

I'd agree with that justice. And thanks for the divi info.

No mishaps overnight and I reckon we could break 4000p tomorrow.

[ruethewhirl] 06/9/2017 20:43

Thanks for the analysis, sure there's value here.

[justiceforthemany] 06/9/2017 19:03

5.09c/share so based on today's exchange rate = 3.9p/share

Looking ahead and what is a fair share price here?
I know brokers have been in the 6000p range which seems a way off at the moment.

However based on EPS of $5/share and the current exchange rate you can see where they are getting this target from.

AZN and GSK both trade on P/E's around 15. GSK is hardly a 'growth' share. Merck, Novartis & Co trade in the high 20's.

Being negative lets say EPS next year falls 10% due to 'competition' and the £ strengthens (unlikely) so $1.35 = £1

Even then on a P/E of 15 the share price should be 5000p+